Rapid Micro Biosystems (NASDAQ:RPID) Releases Earnings Results, Misses Expectations By $0.07 EPS

Rapid Micro Biosystems (NASDAQ:RPID) issued its quarterly earnings results on Wednesday. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07), Zacks reports. The company had revenue of $8.00 million during the quarter, compared to the consensus estimate of $7.60 million. Rapid Micro Biosystems had a negative return on equity of 95.40% and a negative net margin of 140.30%.

Here are the key takeaways from Rapid Micro Biosystems’ conference call:

• Revenue and placements improved. Q1 revenue rose 11% year over year to $8 million, driven by 6 Growth Direct system placements, record consumables growth, and stronger recurring revenue, which reached 63% of total revenue.
• Gross margin is improving and expected to keep rising. First-quarter gross margin was 5%, up 8 points from Q4 2025, and management expects positive product gross margin in Q2 with full-year gross margin around 20% and a mid-20% exit rate in Q4.
• MilliporeSigma partnership is expanding the opportunity. Management said the collaboration is broadening placement opportunities, adding exclusive validation/maintenance services for MilliporeSigma-sold systems, and could also support future sourcing and supply agreement benefits.
• Demand pipeline appears healthy, especially in Asia and large accounts. The company highlighted strong engagement with large biopharma customers, first-system placement in China, and growing interest in enterprise-wide automation across the Asia-Pacific region.
• 2026 guidance was reaffirmed despite a larger Q1 loss and cash usage. Rapid Micro maintained full-year revenue guidance of $37 million-$41 million and 30-38 system placements, while Q1 net loss widened to $14.3 million and cash fell to $23 million, though management said liquidity remains supported by a $25 million credit facility.

Rapid Micro Biosystems Trading Down 6.9%

Shares of RPID stock traded down $0.17 during trading hours on Thursday, hitting $2.31. 47,220 shares of the company’s stock traded hands, compared to its average volume of 236,787. The stock has a market cap of $104.92 million, a PE ratio of -2.15 and a beta of 1.52. Rapid Micro Biosystems has a 12 month low of $2.01 and a 12 month high of $4.94. The stock’s 50 day simple moving average is $2.66 and its 200 day simple moving average is $3.35. The company has a quick ratio of 2.36, a current ratio of 3.31 and a debt-to-equity ratio of 0.57.

Wall Street Analyst Weigh In

RPID has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapid Micro Biosystems in a report on Tuesday, April 21st. Wall Street Zen cut Rapid Micro Biosystems from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Insider Buying and Selling

In other Rapid Micro Biosystems news, COO John J. Addington Wilson sold 9,603 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $4.32, for a total transaction of $41,484.96. Following the completion of the sale, the chief operating officer owned 316,762 shares of the company’s stock, valued at approximately $1,368,411.84. This represents a 2.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Sean M. Wirtjes sold 17,254 shares of the company’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $3.92, for a total transaction of $67,635.68. Following the completion of the sale, the chief financial officer directly owned 563,674 shares in the company, valued at approximately $2,209,602.08. This represents a 2.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 95,989 shares of company stock valued at $385,365 over the last ninety days. 12.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Rapid Micro Biosystems

A number of institutional investors and hedge funds have recently modified their holdings of RPID. Millennium Management LLC bought a new position in shares of Rapid Micro Biosystems during the 4th quarter worth about $338,000. 683 Capital Management LLC bought a new stake in Rapid Micro Biosystems during the fourth quarter worth $350,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Rapid Micro Biosystems in the fourth quarter valued at about $71,000. Barclays PLC purchased a new position in Rapid Micro Biosystems during the fourth quarter worth about $72,000. Finally, Marshall Wace LLP bought a new stake in Rapid Micro Biosystems in the 4th quarter worth about $182,000. 52.60% of the stock is currently owned by institutional investors.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.